SBC Medical Group Holdings (SBC) investor relations material

Executive summary

• Q2 2026 revenue rose 13–13.4% year-over-year to $49–$49.2 million, with net income attributable to shareholders up 335% to $10.7–$11 million, driven by higher management services revenue, AI-enabled enhancements, and network expansion.

• Adjusted EBITDA increased 32% year-over-year to $20 million, with margin expanding to 41%.

• Strategic focus on AI-driven operational efficiency, multi-brand expansion, and global growth, especially in the U.S. and Southeast Asia.

• Longevity and non-aesthetic healthcare positioned as future growth pillars alongside core aesthetic business.

• Clinic network expanded to 287 locations, with customer visits up 10% year-on-year and average spend per visit up 9% to $287.

Financial highlights

• Q2 2026 total revenues: $49–$49.2 million (+13–13.4% YoY); net income: $10.7–$11 million (+335% YoY); adjusted EBITDA: $20 million (+32% YoY).

• Net income margin rose to 21.7–22% (+16pt YoY); adjusted EBITDA margin reached 41% (+6pt YoY).

• Basic EPS for Q2 2026 was $0.10 (+400% YoY).

• Cash and cash equivalents at quarter-end: $184–$184.3 million; capital ratio: 64.9%.

• Operating cash flow for H1 2026: $31.7 million, up from a prior-year outflow.

Outlook and guidance

• AI-enabled platform and revised service agreements expected to drive sustainable growth in clinic locations, average fee per clinic, and service breadth, with $15 million in annualized management service revenue anticipated.

• Continued strong growth in customer volume and unit price expected, with further improvements anticipated in Q3 and Q4.

• Targeting 1,000 clinics by 2035, with a growing share from non-aesthetic healthcare and entry into the Longevity market.

• U.S. and Southeast Asia strategies focus on asset-light expansion and leveraging local partnerships.

• Cash reserves and operating cash flow expected to be sufficient for working capital needs over the next 12 months.